Pharmacosmos
From Wikipedia, the free encyclopedia
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals, Healthcare |
| Founded | 1965 |
| Headquarters | Holbaek, Denmark |
Key people | Tobias S. Christensen (President and CEO), Jacob Tolstrup (Chairman of the Board) |
| Products | Monofer, Cosmofer, Uniferon, Pharmacosmos Dextrans |
Number of employees | 500 (2020) |
| Website | www.pharmacosmos.com |
Pharmacosmos is a pharmaceutical company specialized in treatment of iron deficiency anemia.[1]
Operations
Pharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen, M.D., Ph.D.[2]
Pharmacosmos' corporate headquarters, manufacturing facilities and research laboratories are located in Holbaek, Denmark (Scandinavia). The company has its own marketing, sales and services operations in Denmark and US, UK, Ireland, Germany, Sweden, Norway and China.[3] In other geographies, the company partners with other pharmaceutical companies responsible for local marketing, sales and distribution of its pharmaceuticals brands. The company does not disclose its revenues.[4]
Manufacturing facilities
Pharmacosmos' manufacturing facility is approved according to current Good Manufacturing Practice (GMP) by the European Medicines Agency (EMA) and by the U.S. Food and Drug Administration (FDA).
Research and development
The company has an ongoing clinical development program aimed at improving treatment options for patients with iron deficiency anemia. In 2010, Pharmacosmos' clinical program included three international clinical studies focused on treatment of iron deficiency anemic patients within nephrology, gastroenterology and hematology/oncology.[5][6][7]
